Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6508908 | 0.86 | ITGA4 (0.80) | ITGA4ITGB1 | |
| SCHEMBL6530895 | 0.82 | ITGB1 (0.78) | ITGA4ITGB1 | |
| SCHEMBL6509932 | 0.82 | ITGB1 (0.68) | ITGA4ITGB1 | |
| SCHEMBL7614114 | 0.80 | ITGB1 (0.73) | ITGA4ITGB1 | |
| SCHEMBL7246708 | 0.79 | ITGA4 (0.77) | ITGA4ITGB1 | |
| SCHEMBL6530242 | 0.79 | ITGA4 (0.73) | ITGA4ITGB1 | |
| SCHEMBL6509079 | 0.79 | ITGB1 (0.84) | ITGA4ITGB1 | |
| SCHEMBL6530110 | 0.78 | ITGB1 (0.83) | ITGA4ITGB1 | |
| SCHEMBL5368332 | 0.78 | ITGB1 (0.66) | ITGA4ITGB1 | |
| SCHEMBL7610444 | 0.77 | ITGA4 (0.74) | ITGA4ITGB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050215598-A1 | Phenylalanine derivatives | CELLTECH R&D LTD. (GB) | 2005-09-29 | — | — | US | disclosed |
| US-20030166691-A1 | Phenylalanine derivatives | ARCHIBALD SARAH CATHERINE (GB) | 2003-09-04 | — | — | US | disclosed |
| US-6555562-B1 | 2-Carboxybenzoyl-(N'-3,5-dichloroisonicotinoyl)-L-4aminophenyl alanine, for example; inhibit the binding of alpha-4 integrins to their ligands, use to treat immune or inflammatory disorders | CELLTECH R&D LIMITED (GB) | 2003-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030166691-A1 | Phenylalanine derivatives | VCAM1, PAH, ITGB4 | ITGA4 4/4885ITGB1 6/4885 |
| US-20050215598-A1 | Phenylalanine derivatives | PAH, ITGB4, VCAM1 | ITGA4 4/4885ITGB1 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.